Health Desk: 02 February 2018: Novo Nordisk, the world's biggest insulin maker, has teamed up with local Eskayef Pharmaceuticals to set up a state-of-the-art manufacturing facility in what can be viewed as a pat on the back to Bangladesh's pharmaceutical sector.
The Danish pharmaceutical giant has six such production facilities outside of its home country but this is the first time that it has partnered with a foreign company to set up a plant.
“It is a great moment of honor for Eskayef Pharmaceuticals and I think even more importantly for Bangladesh,” said Latifur Rahman, chairman and chief executive of Transcom Group, the parent company of Eskayef Pharmaceuticals. Rahman's comment came at an agreement signing ceremony between the two companies, held yesterday at the capital's Pan Pacific Sonargaon hotel.
The production facility, which will be set up at a cost of Tk 300 crore, is expected to be complete in three years.
The Danish pharmaceutical giant in partnership with Eskayef has been manufacturing human insulin vials in Bangladesh since 2012, but pen-filled modern insulin products are still imported from Denmark.
It is one of the defining moments for Novo Nordisk in Bangladesh, said Sebnem Avsar Tuna, corporate vice-president for Novo Nordisk Oceania and Southeast Asia regions. “And it is because Eskayef is a trusted partner for us,” she said.
“There are seven million or more diabetic patients in Bangladesh and today we signed a commitment for them,” said Lars Bo Smidt, corporate vice-president for finance and operations at Novo Nordisk's Africa, Asia, Middle East and Oceania operations.
Zahid Malik, state minister for health and family welfare, said he hopes the prices will be within the means of the common people and the quality one of the best in the world.